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Abstract: Premenstrual dysphoric disorder (PMDD) is estimated to affect 3%–8% of  reproductive 
age women. Multiple therapeutic modalities have been evaluated with varying efficacy for the 
associated somatic and mood symptoms. The majority of older studies had shown that oral 
contraceptive pills (OCs) were most effective for the physical symptoms. However, newer OCs 
containing a novel progestin, drospirenone, have shown promise in alleviating both the somatic 
and affective/behavioral symptoms. This progestin, which is a derivative of spironolactone, has 
both antimineralocorticoid and antiandrogenic activity. A 24/4 formulation containing 20 µg of 
ethinyl estradiol has been found effective in randomized double-blind placebo-controlled trials 
utilizing established scales documenting symptoms associated with PMDD. Multiple studies 
have shown that drospirenone-containing OCs are safe without evidence of clinically adverse 
effects on carbohydrate metabolism, lipids, blood pressure, weight, serum potassium or increased 
thrombotic events compared to other low dose OCs. In addition, significant improvements have 
been demonstrated in acne, hirsutism, and fluid retention symptoms. Several open label studies 
demonstrated good patient compliance and reported satisfaction with the method. Because of 
the significant placebo effect demonstrated in the blinded placebo-controlled trials, additional 
large randomized placebo-controlled trials are needed to confirm the efficacy of the drospirenone 
OCs in the treatment of PMDD. However, this OC formulation appears to be a promising 
therapeutic modality.
Keywords: drospirenone, premenstrual dysphoric disorder, premenstrual syndrome, oral 
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Introduction
Many studies have been conducted to evaluate potential treatment modalities for 
premenstrual dysphoric disorder (PMDD) and premenstrual syndrome (PMS). 
Recently, new oral contraceptive pills (OCs) containing drospirenone have shown 
promising results with respect to both the physical and mood symptoms associated with 
these clinical entities. This paper will provide a nonsystematic review of the literature 
on the use of drospirenone-containing OCs for the treatment of PMDD/PMS.
Definition
Premenstrual syndrome (PMS) is the term used to describe an array of predictable 
physical, cognitive, affective, and behavioral symptoms that occur cyclically during 
the luteal phase of the menstrual cycle and resolve quickly within a few days of 
onset of menstruation.1 Some of the common physical symptoms include breast 
tenderness, abdominal bloating, headache, swelling of extremities, fatigue, acne, International Journal of Women’s Health 2009:1 86
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and food cravings/increased appetite. Common affective 
symptoms are irritability, anxiety/tension, labile mood, 
crying, depression, expressed anger, confusion, forgetful-
ness, sleep disturbance, and social isolation/withdrawal.1–5 
It is estimated that 70%–90% of menstruating women 
have some degree of these symptoms before menses with 
20%–40% describing them bothersome enough to impair 
daily functioning and classified as PMS.2 A subset of women 
experiencing premenstrual symptoms includes the 3%–8% 
who have very severe symptoms and functional impairment 
which adversely affects their quality of life. These women 
are classified as having premenstrual dysphoric disorder 
(PMDD).2
Research criteria for PMDD are listed in the Diagnostic 
and Statistical Manual of Mental Health Disorders, 4th 
edition text revision (DSM IV TR) from the American 
Psychiatric Association.5 Although PMDD symptoms are 
focused more on mood, there is overlap between the criteria 
for PMS listed in the American College of Obstetricians 
and Gynecologists (ACOG) practice bulletin published in 
20001 and the DSM IV TR criteria for PMDD.5 Studies 
in the gynecologic literature do not always draw a clear 
distinction between the two. Johnson6 and Speroff and Fritz7 
both conclude that it may not be useful to try to differentiate 
between these entities. PMDD may represent severe PMS 
with impairment. Halbriech8 further discusses that there may 
be a number of women, up to 13%–18% of reproductive 
age women, who would benefit from treatment because of 
symptom severity that is clinically relevant even though they 
do not meet the minimum number of symptoms required in 
the DSM IV TR to meet the classification for PMDD.
Etiology
Although the exact etiology of PMS/PMDD is not known, 
the current literature suggests that the symptomatology is 
probably the result of an interaction between sex steroids 
and central neurotransmitters.9 Endorphins, γ-aminobutric 
acid (GABA), and serotonin have been implicated.6,10–13 
Studies have demonstrated reduced GABA receptor 
sensitivity and reduced plasma GABA in the luteal phase 
as well as possible serotonergic dysregulation with reduced 
serotonergic function in the luteal phase. Some of the 
physical symptoms may be related to the renin–angiotensin–
aldostersone system (RAAS).13 Gonadal hormones influence 
the RAAS such that estrogen increases water retention and 
bloating through mineralocortioid activity and induction of 
synthesis of angiotensinogen. Progesterone counteracts these 
effects through antimineralocortioid activity. Although the 
levels of sex steroids such as estrogen, progesterone, and 
testosterone are normal, studies have suggested that women 
with PMS/PMDD may be more sensitive to normal cyclical 
hormonal fluctuations and have an abnormal response to 
normal hormone changes. One study supporting this theory14 
demonstrated a recurrence of symptoms in a group of women 
who were suppressed with the gonadotropin-releasing 
hormone agonist when given estrogen and progesterone. 
Some authors have suggested that this vulnerability may 
be in part related to serotonin.10
Impact on quality of life
PMS and PMDD have significant impact on quality of life. 
Studies have shown that individuals with moderate/severe 
PMS/PMDD are more likely to experience health- and work-
related problems.15–17 Women with premenstrual symptoms 
have significantly higher rates of absenteeism from work 
and poorer productivity. Statistically significant increases in 
direct medical costs related to outpatient visits, laboratory 
tests, and radiology services have been demonstrated in 
addition to the costs related to work attendance and decreased 
productivity.
The consequences of PMS/PMDD have been demon-
strated in studies in many parts of the world. Hylan18 studied 
1,045 subjects from the United States, United Kingdom, 
and France of whom 23%–31% were classified as having 
severe premenstrual symptomatology. Interference with 
home, work, school and social life increased with severity 
of reported symptoms. There were similarities across the 
three countries with the most commonly reported symptoms 
being irritability/anger, fatigue, physical swelling/bloating, 
and weight gain.
In another recent study, Yang19 demonstrated a significant 
quality of life burden from PMDD in relation to both physical 
and mental health issues. Mental/emotional health issues 
were most prominent, with PMDD having a greater impact 
on body pain and mental health scales than chronic back 
pain. Finally, a study conducted by Robinson20 addressed 
interpersonal relationships in more detail demonstrating 
that individuals who had symptomatology classified as 
moderate to severe PMS/PMDD, through a DSM-IV adapted 
classification of severity, reported impact on significant 
interpersonal relationships. Ninety-two percent of these 
women had one affected social- or work-related domain, 
with 61.5% having impact at work or school, 59.3% with 
household activities, 83% in the relationship with their 
husband, 77.6% in the relationship with their children, and 
68.5% in their social life.International Journal of Women’s Health 2009:1 87
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Treatment modalities
There is no single treatment modality that has been universally 
effective, and most studies have found conflicting results. 
Furthermore, many studies have not involved controlled 
clinical trials. Treatment interventions have included 
pharmacologic and nonpharmacologic modalities such as 
lifestyle change, stress management, and cognitive behavioral 
therapy, as well as minerals, vitamins, herbal preparations, and 
dietary manipulations. There is insufficient evidence to date 
to definitively recommend any of these non-pharmacologic 
modalities.21,22 Pharmacologic interventions have included 
hormonal therapies and psychotropic medications.22 
OCs and GnRH agonists have been utilized to suppress 
ovulation, cyclic changes, and endogenous sex hormone 
variability.1,6,7,23–25 Selective serotonin reuptake inhibitors 
(SSRIs), serotonin-norepinephrine reuptake inhibitors 
(SNRIs), as well as anxiolytics and other antidpressants, 
have been used to address somatic and/or affective 
symptoms.12,26–36 Some of the somatic and negative mood 
symptoms such as breast tenderness, bloating, and weight 
gain from fluid retention, irritability, and depression have 
also been demonstrated to improve with use of the diuretic 
spironolactone.37,38
With respect to pharmacologic options, SSRIs have been 
considered the drugs of choice for severe PMS/PMDD.26 
Placebo-controlled studies have shown improvement in both 
physical and mood symptoms39 and a recently published 
meta-analysis confirmed SSRI efficacy.40 SSRIs are usually 
well tolerated and can be used in low doses. However, 
SSRIs are not without side effects which include insomnia, 
gastrointestinal disturbance, fatigue, dizziness, sweating, 
and sexual function disturbance.39 Overall, studies of 
OCs have shown mixed effectiveness and in some cases 
worsening of symptoms. In general, OCs appear to have 
more impact on the physical symptoms rather than mood-
related symptoms.1,6,23,41 However, a newer OC containing 
the progestin drospirenone, which is a derivative of 
spironolactone, has been shown to relieve both physical and 
mood symptoms. The remainder of this article will address 
use of OCs containing drospirenone in the management of 
PMS/PMDD.
OC formulations
Before addressing the specific OCs containing drospirenone, 
it is important to understand some key points about OC 
formulations. Combination oral contraceptive pills (COCs) 
contain both an estrogen and a progestin. There are essentially 
three variables to consider in OC formulations. The first 
variable is the dose of estrogen. All available COCs contain 
ethinyl estradiol (EE) in varying amounts, with the lowest 
available dose being 15 µg EE and the highest 50 µg EE. 
The EE component is primarily responsible for the fluid 
retention side effects of the COCs. Lowering the dose of EE 
has decreased many side effects; however, it has also been 
associated with a higher incidence of intermenstrual bleeding 
than the original formulations, which all contained greater 
than 50 µg EE.42 In addition, although the half-life of EE is 
constant, with the lower estrogen doses used in the more 
recent formulations, EE is cleared from the circulation within 
only 2–3 days after the last active pill. This rapid clearance 
may allow FSH levels to rise and follicular development 
to occur within several days of the hormone-free interval 
in the OC pack.43
The second variable is the type and dose of the progestin. 
There are three classes of  progestins (synthetic progesterone-like 
compounds) in COCs: progesterone (17α-acetoprogesterone) 
derivatives, testosterone (19-nortestosterone) derivatives, 
and sprinolactone (17α-spironolactone) derivatives. The 
17α-acetoprogesterone derivatives, referred to as pregnanes, 
are similar to the structure of progesterone itself. The testos-
terone derivatives are the most commonly used and fall into 
two major categories: estranes (norethindrone, norethindrone 
acetate, and ethynodiol acetate) and gonanes (norgestrel, 
levonorgestrel, norgestimate, desogestrel, and gestodene). 
By chemically altering testosterone, most of the androgenic 
properties are removed or substantially decreased, but 
all retain at least some degree of androgenicity. The only 
spironolactone-derived compound is drospirenone making 
this progestin the only progestin not derived from a sex 
steroid.
The effects of progestins are related to the compound’s 
interactions with a number of receptors, including the 
receptor for progesterone, androgens, estrogen, glucocorti-
coids, and mineralocorticoids. The ability to either stimulate 
or block native interaction with such receptors mediates both 
the desirable and the undesirable side effects of some of 
the available progestins. Of note, acne and weight gain are 
commonly cited side effects of COCs which could be mediated 
by the progestin effect on the androgen and the glucocorticoid 
receptors respectively. Despite the efficacy of first and second 
generation progestins in preventing pregnancy, significant 
undesirable side effects, such as acne, water retention, and 
bloating limit the use for other indications. Third generation 
alternatives, such as norgestimate or desogestrel, have some 
advantages but still possess some androgenic activity. Unlike 
the other progestins, drospireone has antimineralocorticoid International Journal of Women’s Health 2009:1 88
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(aldosterone antagonist) and antiandrogenic properties44 and 
is pharmacologically similar to endogenous progesterone.45 
The lack of antimineralocorticoid activity in other progestins 
may account for the sodium and water retention, minor 
elevations in blood pressure, and “pill hypertension” seen 
in some individuals.46 The antimineralocorticoid effect of 
drospirenone has the potential to counteract the influence 
of estrogen-induced fluid retention that can affect some 
women who use low-dose COCs and reduce the incidence 
and severity of side effects related to fluid retention, such 
as swelling of the extremities, breast tension, and body 
weight. The antiandrogenic effects have the potential to 
positively impact dermatologic conditions such as acne and 
hirsutism.
With the unique characteristics of drospirenone, a COC 
containing EE and this novel progestin was believed to show 
promise in areas where other OCs have fallen short. In cohort 
studies of women with premenstrual symptoms comparing 
drospirenone and other progestins, there were beneficial 
trends when compared to other formulations. Foidart 
demonstrated these trends when comparing drospirenone to 
desogestrel.47 Sangthawan found that the prevalence of water 
retention, in addition to other potentially negative effects 
(weight gain, irritability, anxiety) was reduced by half in 
the EE/drospirenone group while remaining unchanged in 
an EE/levonorgestrel group.48
The third variable is the dosing pattern. The majority of 
COCs are administered in a standard 21/7 regimen, such that 
the EE and the progestin are given on days 1–21, followed 
by placebo pills on days 22–28, constituting the hormone-
free interval. As with the estrogenic component, the lower 
doses of the progestins in the newer COCs are also cleared 
from the circulation within a few days after stopping the 
steroid-containing pills, allowing lutenizing hormone (LH) 
levels to rise. Therefore, ovulation may occur if the new 
cycle of active pills is not started exactly seven days after 
the last active pill was taken. In one randomized trial with 
a 20 µg EE formulation, when the hormone-free interval 
was five days, in lieu of the historical seven days, there was 
greater suppression of ovarian follicular size and endogenous 
estradiol levels.49 Use of a 3–4 day hormone-free interval 
appears to provide a sufficient level of both EE and progestin 
in the circulation to suppress both gonadotropins until the 
new cycle of active pills is begun. Newer formulations of 
COCs (24/4) have decreased the hormone-free interval to 
four days by providing active medication on days 1–24 and 
placebo pills on days 25–28. The decrease in the number 
of days without steroid ingestion should result in constant 
suppression of  LH and follicle-stimulating hormone (FSH) 
levels and prevent follicular growth during the hormone-
free interval. Constant inhibition of follicular development 
and endogenous estradiol synthesis throughout each month 
of oral contraceptive use should decrease the incidence of 
unscheduled bleeding as well as the incidence of escape 
ovulation and pregnancy that occurs with typical oral 
contraceptive use. In addition, the shortening of the hormone-
free interval should decrease several of the adverse hormonal 
withdrawal symptoms experienced during the seven day 
hormone-free interval in the standard COC regimens.
OC formulations containing 
drospirenone
Two OCs are available which contain the progestin 
drospirenone. One is a standard 21/7 formulation containing 
30 µg of ethinyl estradiol and the other is a 24/4 formulation 
containing 20 µg of ethnyl estradiol. Drospirenone has 
properties that are similar to its analog, spironolactone – an 
aldosterone antagonist, with antimineralcorticoid activity 
resulting in naturietic and antihypertensive qualities. The 
antimineralocorticoid effect of the 3 mg dose of drospireone, 
contained in the commercially available OCs, is equivalent 
to 25 mg of spironolactone. The 24/4 formulation which con-
tains a lower dose of EE (20 µg) with 3 mg of drospirenone 
and shorter hormone-free interval is proposed to minimize 
hormone withdrawal effects and have less fluid retention and 
stimulation of the renin–angiotensin–aldosterone system. Use 
of drospirenone with its long half life and antialdosterone 
and antiandrogenic qualities appears to be an excellent choice 
for a 24/4 OC regimen, particularly with respect to physical 
side effects and mood symptoms.
Impact of drospirenone-containing 
OCs on PMS and PMDD
There are a number of studies evaluating the impact of OCs 
containing drospirenone on PMS and PMDD. However, only 
a few were conducted as randomized placebo-controlled 
studies. This is especially important because of the potential 
for strong placebo effects in open trials.
The first double-blind placebo-controlled study was 
published by Freeman and colleagues50 in 2001 and 
included 82 women who fit the diagnosis of PMDD per 
the DSM IV manual criteria. The subjects were evaluated 
after random assignment to drospirenone 3 mg/EE 30 µg 
(Yasmin) or placebo for three cycles. Symptoms were 
evaluated by the Calendar of Premenstrual Experiences 
(COPE) scale, Beck Depression Inventory (BDI), and Profile International Journal of Women’s Health 2009:1 89
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of Mood States (POMS). Subjects’ ratings were compared 
to their baseline scores. Although there was more numerical 
improvement in total COPE scores, BDI, and POMS when 
comparing the drospirenone OC to placebo, the only items 
that demonstrated statistical significance were factor 3 of the 
COPE scale which included acne, increased appetite, and 
food cravings. This study was limited by not having adequate 
power but was suggestive of positive effects of drospirenone 
3 mg/EE 30 µg on PMDD symptoms.
In a second multicenter double-blind placebo-controlled 
crossover study by Pearlstein and colleagues,51 64 subjects 
meeting DSM IV criteria for PMDD were given the either 
placebo or a 24/4 regimen of 20 µg of EE and 3 mg of 
drospirenone. After three cycles, they had a washout period 
and were then switched to the other regimen for another three 
cycles. Potential subjects were excluded if they had another 
concurrent mental health disorder including depression, 
anxiety, eating disorder, bipolar, psychosis, somatoform, 
dysthymic, or drug/alcohol problems in the previous two 
years. Symptoms were measured by the Daily Record of 
Severity of Problems Scale (DRSP), the Endicott Quality of 
Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), 
the Clinical Global Impressions-Improvement (CGI-I), 
and the Premenstrual Tension Scales (PMTS). There was 
statistically significant improvement on the total DRSP score 
comparing the drospirenone group to the placebo group with 
significant changes in the individual items including mood 
symptoms, irritability, anxiousness, difficulty concentrating, 
fatigue, appetite, and breast symptoms. In addition, there 
was significant improvement in functional impairment 
items such as productivity, social activities, and social 
relationships. Statistical significance was also found in the 
PMTS scores comparing the treatment to placebo group and 
in the Q-LES-Q showing significant changes in all items 
including overall life satisfaction except for the medication 
satisfaction rating. Statistically significant differences were 
also found in the CGI-I scale with 62% of women on the 
drospirenone preparation versus 32% on placebo showing 
positive responses. There was no significant difference in the 
total DRSP score comparing pill pack days 21–24 to 25–28 
in the drospirenone group suggesting that the subjects did not 
experience hormone withdrawal symptoms and supporting 
the effectiveness of the 24/4 regimen.
A third study by Yonkers and colleagues52 involved a 
multicenter, double-blind randomized placebo-controlled 
trial with 450 women assigned to the 24/4 regimen of 20 µg 
EE and 3 mg of drospirenone (Yaz) or placebo and included 
two run-in cycles followed by three treatment cycles. 
Subjects were evaluated with the DRSP, Q-LES-Q, the 
CGI-I, and PMTS. Similar to the Pearlstein study,51 there 
were statistically significant improvements in the CGI-I 
and PMTS comparing the treatment group to placebo. 
Statistically significant improvements in the DRSP scores 
were seen in the group with the active preparation com-
pared to placebo in all of the physical and mood symptoms 
items on the DRSP questionnaire, as well as the functional 
impairment items including productivity, social activities, 
and quality of relationships. Similar to the Pearlstein study, 
there were also statistically significant differences in the 
Q-LES-Q for the first fourteen items. However, overall 
life satisfaction as well as medication satisfaction was not 
significant. As in the Pearlstein study, comparison of DRSP 
scores in the active group between days 21–24 and 25–28 
of the pack did not show statistically significant differences 
supporting the absence of withdrawal symptoms with the 
24/4 formulation.
In a published abstract from a poster presentation at the 
May 2008 ACOG meeting, Yonkers53 reported on a further 
analysis by symptom category in which the DRSP items 
were grouped into the three categories of interpersonal 
relationships, food, or water retention. The scores were 
evaluated for the three treatment cycles and OC users were 
compared to the placebo group. Interpersonal relationships 
demonstrated the largest percent change followed by food 
and then water-retention symptoms. Statistically significant 
improvements were seen in all three cycles starting with 
the first active cycle. Since this is only a published abstract 
and the related full article is not available, it is not possible 
to completely evaluate the data; however, the results from 
the published abstract are promising.
Strengths and limitations of studies
The greatest strength of the referenced literature is the 
randomized nature of these three studies and the use of 
a double blind placebo controlled design. The Yonkers52 
and Pearlstein51 studies also used similar evaluation tools 
which allows for easier comparison of results. However, 
there are limitations that should be considered. Two of 
the studies had small sample sizes (82 and 64 subjects) 
and the Freeman study50 did not have enough power to 
effectively evaluate the study question. All of the studies 
had follow-up which was limited to only three cycles 
thereby limiting evaluation of long term efficacy. None of 
the studies compared the drospirenone OC to another OC 
so it is not possible to evaluate whether the drospirenone 
OC is superior to others on the market. Heterogeneity International Journal of Women’s Health 2009:1 90
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is also an important consideration since completers in 
each study may have differed from non-completers, thus 
negatively impacting the generalizability of the results. 
Loss to follow-up was significant in all of the three studies. 
In Freeman, although there was no statistically significant 
difference in discontinuation rates between the drospirenone 
OC and placebo groups, 50% of the treatment group and 30% 
of the placebo group discontinued the study. In Pearlstein, 
total losses were 64%, including 58% for the group that 
received drospirenone first and 70% in the group randomized 
to use of placebo first. In the group that took the OC first, the 
noncompleters had a higher baseline mean for the DRSP than 
the completers, indicating more severe baseline symptoms. 
In terms of clinical relevance, those subjects actually may be 
ones most likely to benefit, but data is not available because 
they did not complete the study. Yonkers and colleagues also 
had subject attrition although that study had fewer losses 
than Pearlstein with a total of 27% including 31% for the 
drospirenone group and 23% for placebo.
Another limitation of all of these studies is the existence 
of the placebo effect as indicated by the fact that the placebo 
groups had high response rates. For example, in Freeman’s 
paper, a 43% placebo response was reported. In Yonker’s 
paper, 36% of participants given the placebo met criteria 
for “responders” in contrast to 48% of the women given the 
drospirenone OC. The number of individuals who need to 
be treated to see an actual benefit attributed to the therapy 
is larger as the placebo effect increases. As discussed in 
the recent Cochrane review,54 depending on the size of the 
placebo effect, it could be less expensive and less risky to 
treat PMDD with a placebo rather than a COC. Although 
the Pearlstein and Yonkers’ studies strongly suggest that 
drospirenone with 20 µg EE in a 24/4 formulation may 
help treat premenstrual symptoms in women with PMDD, 
the strong placebo effect makes evaluation of the clinical 
significance of the difference more difficult to interpret. 
More randomized placebo controlled studies are needed to 
further evaluate this issue.
Results of other studies
Several studies have been conducted to evaluate the effects 
of an OC containing drospirenone on quality of life. 
These additional studies include Borenstein,55 Endrikat,56 
Taneepanichskul,57 Sangthawan,48 Apter,58 Borges,59 Brown,60 
and Parsey.61 These studies used standardized questionnaires 
such as the Menstrual Distress Questionnaire (MDQ), 
Medical Outcomes Short Form (SF-12), Women’s Health 
Assessment Questionnaire, and the Psychological General 
Well Being Index and compared ratings on physical and 
emotional/mood symptoms over several cycles ranging 
from 2–13. The various studies demonstrated statistically 
significant improvements in premenstrual symptomatology, 
including water retention, abdominal bloating, breast tension/
tenderness, weight gain, swelling, skin disorders including 
undesirable hair change, and food cravings, as well as 
improvement in negative affect including crying, loneliness, 
anxiety, restlessness, irritability, mood swings, depression, 
and tension. Among these various studies, there was also 
a statistically significant improvement shown in reported 
ability to perform usual activities, general sense of well being, 
self control, and vitality.
Overall these studies have limitations. Although some 
were large multicenter studies, others had small sample 
sizes. Further, although some compared the effects of an 
OC with drospirenone to an OC with another progestin, 
many were open-label noncomparative studies and subject 
to difficulty in interpretation because of potential substantial 
placebo effects. The studies also used a variety of different 
instruments which make comparison between them more 
difficult. Despite these limitations, the results do show 
common trends in improvement in PMS/PMDD symptoms 
and strongly suggest the need for further evaluation and 
confirmation of the results with more rigorously designed 
clinical trials. They also provide some longer term follow up 
than the three randomized double blind placebo controlled 
studies discussed above.
Side effects of dropirenone-
containing OCs
Many studies have evaluated the side effects of drospirenone-
containing OCs. Although some of these studies were not 
placebo-controlled or double-blinded, some of the outcomes 
were related to laboratory tests and clinical measurements 
such as blood pressure, weight, and serum potassium levels, 
which are objectively measured by an instrument and 
therefore raise less concern about the placebo effect seen in 
subjective behavioral outcome measures. These side effects 
include both negative and potentially beneficial side effects. 
Beneficial side effects of an OC containing drospirenone 
would be anticipated because of the antiandrogenic and 
antimineralocorticoid activity of this progestin.
Skin
Acne
Studies of OC preparations containing drospirenone 
have shown improvement in acne in terms of severity and International Journal of Women’s Health 2009:1 91
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lesion count.62–65 One open label randomized multicenter 
study62 followed 2,069 women over 13 treatment cycles 
and found a reduction in the incidence of acne from 
21.5% to 7.8% by the end of the study. In a double-
blind study,63 an OC containing drospirenone showed 
improvement which reached statistical significance when 
compared to an OC containing norgestimate. A multicenter 
randomized placebo-controlled double-blind study64 of 
538 14–45-year-old women with moderate acne who were 
evaluated after six cycles demonstrated improvement in 
acne severity and lesion count compared to placebo. This 
study utilized the Investigator Static Global Assessment 
Scale, and demonstrated a statistically significant reduction 
in total lesions (46%) in the treatment group compared 
to placebo (31%) as well as an increase in the number of 
subjects rated as clear or almost clear in the treatment group. 
Finally, a randomized double-blind placebo-controlled 
trial65 included 534 women of reproductive age and showed 
improvement in both lesion counts and a statistically 
significant improvement in both the investigator’s and the 
subject’s self rating of improvement in acne. Compared to 
the placebo group, those in the drospirenone OC group had 
a fourfold greater chance of being rated as clear or almost 
clear at the end of study.
Hirsutism
Two small studies66,67 demonstrated improvement in hirsutism. 
The first66 was an open prospective study of 20 women 
demonstrating a statistically significant improvement in the 
Ferriman–Gallwey score68 after six cycles of a drospirenone 
containing OC. The second67 was a prospective open 
controlled clinical trial with 50 women that showed a 
statistically significant improvement in Ferriman–Gallwey 
scores at both six and 12 months of therapy with a reduction 
of 67% in the score at six months and 78% at 12 months 
compared to baseline.
Cycle control
Multiple studies have demonstrated good cycle control with 
drospirenone-containing OCs.47,58,59,61,62,69 Similar to other 
OCs, intermenstrual bleeding is highest during the first 
cycle and remits during subsequent cycles. Two studies47,62 
which compared users of a drospirenone-containing 
OC to desogestrel found no significant differences in 
intermenstrual bleeding between these two formulations 
over 13 months and 26 months, respectively. In the double-
blind, randomized, placebo-controlled study by Yonkers,52 
25.1% of treatment subjects compared to 4.6% of placebo 
subjects had intermenstrual bleeding. This difference was 
statistically significant but it is difficult to adequately assess 
this finding since the study was limited to three cycles when 
intermenstrual bleeding is most common on all low dose 
OCs. In the smaller similarly designed study by Pearlstein,51 
there was a trend toward increased intermenstrual bleeding 
in the drospirenone group compared to placebo but this was 
not statistically significant (p = 0.067).
Weight
One of the most common complaints among COC users 
is weight gain. Multiple studies have demonstrated stable 
or lower body weight with the drospirenone-containing 
OC.47,58,59,62,69–72 These studies included comparative studies 
demonstrating lower body weight with the drospirenone-
containing OC than a formulation containing desogestrel.
Breast tenderness
Yonkers found a statistically significant difference in breast 
pain complaints between treatment and placebo subjects 
(13.4% vs 5%) in a double-blind, randomized placebo-
controlled study.52 The smaller similarly designed study by 
Pearlstein,51 however, did not demonstrate a statistically 
significant difference between treatment and placebo 
subjects.
Nausea
Yonkers52 found a statistically significant difference in 
complaints of nausea when comparing the drospirenone 
group to placebo (18.6% vs 5%). Pearlstein51 did not find this 
difference to be statistically significant in a smaller similarly 
designed study. It is difficult to know if this symptom would 
have persisted since the Yonkers study only followed subjects 
for three months and this common complaint frequently 
improves after a few pill cycles.
Headache
Neither Yonkers52 nor Pearlstein51 found statistically 
significant differences in complaints of headache when 
comparing the drospirenone group to the placebo group in 
their double-blind placebo-controlled randomized trials.
Safety
Hyperkalemia
One of the primary safety concerns with drospirenone is 
the possibility of hyperkalemia. Because drospirenone 
shares spironolactone’s potassium-sparing characteristic, 
OCs containing this progestin carry a warning about the International Journal of Women’s Health 2009:1 92
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possibility of hyperkalemia in high-risk women.73 Several 
studies have reported on the incidence of hyperkalemia in 
women using drospirenone. In the randomized placebo-
controlled study by Yonkers,52 there were no differences 
in serum potassium between the placebo and OC group. 
In the open-labeled study by Bachmann,69 only four 
of 1,027 subjects had a serum potassium between 5.5–
5.7 mEq/L, and there were no recorded adverse potassium-
related events. Schürmann74 conducted an open-label study 
investigating whether drospirenone alone increased the 
risk of hyperkalemia in subjects with renal impairment. 
Twenty-eight women were divided into three groups clas-
sified as normal renal function and mild or moderate renal 
impairment and were given drospirenone 3 mg/day for 
14 days. There were no significant changes in the mean 
serum potassium concentrations during the 14 days of 
steady state drospirenone treatment. These results included 
25% of subjects who continued to use antihypertensive 
medications that had the potential to elevate their potassium 
concentration during the study. No statistically significant 
or clinically meaningful differences in serum potassium 
concentrations in subjects with renal insufficiency versus 
subjects with normal renal function were found.74 Oelkers70 
investigated the effects of a drospirenone-containing OC 
on serum potassium with different doses of EE (30 µg EE, 
20 µg EE, 15 µg EE) and compared these to an OC with 
levonorgestrel and 30 µg EE. Twenty women with normal 
renal function indices participated in each group. Serum 
potassium did not change significantly during treatment and 
was approximately 4.1 mmol/L in all four groups. Finally, 
one study by Schütt75 evaluated the effect of co-administration 
of estradiol/drospirenone and indomethacin in a randomized 
open-labeled crossover study in postmenopausal women and 
did not find significant changes in serum potassium levels. 
The results of this study would imply that concomitant use 
of NSAIDs with a drospirenone-containing OC should not 
be a concern.
The largest evaluation was a multinational, prospective 
noninterventional cohort study of new users of OCs, includ-
ing drospirenone, levonorgestrel, and other progestin-
containing formulations (European Active Surveillance study 
[EURAS]).76 A total of 58,674 women were followed for 
142,475 women-years of observation. In this investigation, 
28.2% used a drospirenone-containing OC, 26.3% used a OC 
containing levonorgestrel, 44.9% used OCs containing another 
progestin, and 0.6% did not use a combined oral contraceptive. 
Data regarding the incidence of arrhythmias was used as a 
surrogate measure of serum potassium levels. None of the 
99 confirmed new arrhthymias were suggestive of the types 
associated with increased serum potassium. However, potas-
sium levels were not directly measured.
venous thromboembolic events
It is well established that OCs increase the risk of venous 
thromboembolic events (VTE). An important consid-
eration for any new progestin is the evaluation of the 
potential VTE risk. The EURAS study is important 
because it is a prospective multinational study with a 
large number of subjects.76 In this study, the monophasic 
30 µg EE/levonorgestrel products represented 53% of the 
levonorgestrel exposure, which allowed a direct comparison 
of drospirenone to levonorgestrel for OCs containing a 
monophasic dosing pattern of 30 µg of EE. The incidence 
of VTE was 10.2/10,000 women years in the levonorgestrel 
subcohort and 9.1/10,000 women years in the drospirenone 
cohort. Cox regression analysis found a crude hazard ratio 
(HR) for drospirenone of 0.9 (95% confidence interval 
[CI]: 0.5–1.6) and an HRadj of 0.8 (95% CI: 0.5–1.5) indicating 
that there was no evidence of a higher risk of VTE in the 
drospirenone group compared to the levonorgestrel group.
In another large study in the United States, Seeger and 
colleagues collected data from a database maintained by the 
health insurer, United Healthcare.77 The authors identified 
EE/drospirenone initiators along with a comparison group 
of other OC initiators with similar demographic and health 
care characteristics. There were 22,429 EE/drospirenone 
initiators and 44,858 initiators of other oral contraceptive 
initiators who were followed for an average of 7.6 months. 
Cases of thromboembolism were identified through claims for 
medical services and only those claims that were confirmed 
through review of the medical record were considered true 
cases of VTE. There were eighteen cases of thromboembo-
lism in EE/drospirenone subjects (1.3/10,000 woman-years) 
compared to 39 cases (1.4/10,000 woman-years) in the other 
OC initiators. The rate ratio was 0.9 with a confidence interval of 
0.5–1.6 demonstrating no difference in risk of thromboembolism 
between the two groups making the thromboembolism risk of 
a drospirenone OC similar to other COCs.
Blood pressure
No significant adverse affects on blood pressure (BP) were 
found in multiple studies,47,59,61,62,69–71 and in several comparative 
studies the BP was slightly lower in the drospirenone group.
Insulin resistance and glucose tolerance
Multiple studies70,78,79 have demonstrated a lack of clinically 
significant changes in glucose tolerance utilizing oral International Journal of Women’s Health 2009:1 93
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glucose tolerance tests and measurements of glucose and 
insulin levels. These results were evaluated in ranges of six 
to 12 months depending on the study.
Lipids
Overall OCs containing drospirenone show a favorable 
lipid profile with an increase in high-density lipoprotein and 
decrease in low-density lipoprotein cholesterol levels.61,70,79 
Although these studies demonstrated an increase in serum 
triglycerides, the plasma lipid changes were within the 
reference range or did not suggest clinically significant 
atherogenic changes. A study by Klipping79 compared two 
different OCs and did not find significant differences in lipids 
between the subjects taking an OC with drospirenone and 
those taking an OC-containing desogestrel.
Other adverse events
When comparing the drospirenone-containing OC cohort to 
other OC cohorts, the EURAS study did not find any increase 
in arterial thromboembolism or any of 14 other disease 
categories, including malignant neoplasms, benign tumors, 
infection, injury, or in any other organ systems including 
blood-forming, eye, respiratory, endocrine, central nervous 
system, skin, genitourinary, cardiovascular, digestive, and 
musculoskeletal.76 The incidence for cancer of the breast, 
cervix, and uterus were similar or lower when comparing 
the drospirenone group to the other OC cohorts. In addition, 
there were no statistically significant differences in fatal 
outcomes between the drospirenone cohort and the other OC 
cohorts and no causal relationship found for any deaths in 
the drospirenone cohort by the Advisory Council.
Patient satisfaction/compliance
Several studies have addressed patient satisfaction. 
In the open label noncomparative study of 1,018 women by 
Bachmann69 of a 24/4 drospirenone formulation with 20 µg 
of EE, 86% of subjects reported that they were satisfied or 
very satisfied with the treatment and 72.7% reported a desire 
to continue with the study medication. This was associated 
with over 85% reporting improved or unchanged physical 
and emotional well being. Subjects demonstrated excellent 
compliance with 92.6%–95.7% taking 26 or more tablets 
per cycle. In an open-label study of 326 women by Parsey,61 
utilizing the 21/7 30 µg EE formulation drospirenone OC, 
73% did not miss any pills during the study, with 80% 
compliance among subjects who had used OCs in the 
past and 65% for those who were new OC users. Borges59 
found that 84.2% of 241 women given a 21/7 30 µg EE 
formulation of a drospirenone OC in an open-label study 
reported improvement in their premenstrual symptoms and 
that the treatment was successful. Finally, Apter58 studied 
336 subjects in an open label uncontrolled study of a 21/7 
30 EE µg formulation of a drospirenone OC and found that 
86% of the time there was agreement between the investigator 
and subjects regarding symptom improvement with 85% of 
the subjects reported being much or very much satisfied at 
cycle 6 of the treatment protocol.
Conclusions
PMDD/PMS is a significant condition that adversely 
affects quality of life for a subset of menstruating women. 
Randomized placebo-controlled double-blind studies have 
shown that the OCs containing drospirenone, and more spe-
cifically the 24/4 formulation, may significantly improve 
the mood and physical symptoms associated with PMDD 
and improve quality of life issues. Based on large studies in 
Europe and the United States, there do not appear to be any 
increased adverse physiologic or health outcomes related to 
the drospirenone-containing OC compared to other OCs on 
the market. Furthermore, OCs containing drospirenone appear 
to have several beneficial effects including improvement 
in acne, fluid retention symptoms, and hirsutism without 
significant weight gain. Although more double-blinded pla-
cebo-controlled studies are needed, several open label studies 
suggest high rates of patient satisfaction and compliance with 
drospirenone-containing OCs.
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